Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective

@article{Terrault2005ManagementOT,
  title={Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective},
  author={Norah A. Terrault and Bruno Roche and Didier Samuel},
  journal={Liver Transplantation},
  year={2005},
  volume={11}
}
Introduction A total of 5 to 10% of patients undergoing orthotopic liver transplantation (OLT) have hepatitis B virus (HBV)–associated chronic or fulminant liver disease. Long-term survival depends on the prevention of allograft reinfection or the slowing of disease progression in those who have recurrent disease. In the absence of prophylactic measures, the risk of HBV reinfection after OLT is approximately 80% and is related largely to the level of HBV replication at time of transplantation.1… 
Liver transplantation in viral hepatitis: prevention of recurrence.
  • B. Roche, D. Samuel
  • Medicine, Biology
    Best practice & research. Clinical gastroenterology
  • 2008
MANAGEMENT OF HEPATITIS B VIRUS INFECTION IN LIVER TRANSPLANT RECIPIENTS
TLDR
The present review highlights issues pertaining to HBV reinfection and de novo infection in LT recipients with recommendations for its management.
Individualizing hepatitis B infection prophylaxis in liver transplant recipients.
Hepatitis B immunoglobulin in preventing reinfection following liver transplantation
TLDR
The prognosis for hepatitis B-positive transplant recipients was improved by a combination of long-term HBIG and antiviral therapy, in particular lamivudine, which reduced the reinfection rate, in most cases to between 0 and 5%.
Management of Patients with Chronic Hepatitis B Before and After Liver Transplantation: An Update
TLDR
This review summarizes available evidence for the use of different antiviral agents before liver transplantation, the effectiveness of prophylactic agents in preventing recurrent HBV infection post-liver transplants, and the efficacy of several regimens for treating recurrent HBv infection post -liver transplantation.
Hepatitis B and liver transplantation
TLDR
Development of more potent NAs, with low viral resistance, has allowed for reduction and in some cases elimination of use of HBIG in post liver transplant prophylaxis of patients with CHB.
Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years
  • N. Yılmaz, M. Shiffman, R. Fisher
  • Medicine, Biology
    Liver international : official journal of the International Association for the Study of the Liver
  • 2008
TLDR
It is concluded that recurrence of HBV following LT can be prevented in E‐antigen‐positive patients with a combination of HBIG and an anti‐viral agent, and in contrast, recurrence can be prevent in E-antigen-negative patients with H BIG alone.
Hepatitis B Immune Globulin in Liver Transplantation Prophylaxis: An Update
TLDR
Most recent studies support the use of long-term combination therapy of HBIg and antiviral NAs (especially new agents) and there is currently no consensus on a standardized recommendation for therapeutic options that include HBIG administration.
Liver transplantation for hepatitis B-related cirrhosis: recent advances.
TLDR
Combination therapy with hepatitis B immunoglobulin and lamivudine after liver transplantation reduces HBV recurrence and adefovir dipoxil is a safe and effective alternative oral antiviral treatment for lamivUDine-resistant mutant HBV.
11 Management of Recurrent HCV and HBV Infections after Liver Transplantation
TLDR
Efforts of transplant physicians to manage recurrent HCV infection in order to optimize outcomes and to slow down the progression of HCV-related liver disease are the greatest challenge.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 127 REFERENCES
Lamivudine for hepatitis B in liver transplantation: a single-center experience.
TLDR
Given the safe clinical profile and high efficacy in the prevention of disease recurrence, lamivudine will favorably change the outlook of liver transplantation for HBV and achieve viral DNA clearance in almost all patients.
Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation.
TLDR
Evidence is provided that the introduction of lamivudine may favorably alter the prognosis of patients infected with hepatitis B virus who underwent liver transplantation and this drug may be an important acquisition for antiviral prophylaxis in HBV-infected liver recipients.
Increasing applicability of liver transplantation for patients with hepatitis B–related liver disease
TLDR
Based on the experience, hepatitis B patients, including those with active viral replication, should not be excluded from liver transplantation, and excellent long‐term results can be achieved in hepatitis B Patients after liver transplants with modern strategies, and survival rates are similar to other indications.
Liver Transplantation in Asian Patients With Chronic Hepatitis B Using Lamivudine Prophylaxis
TLDR
Asian patients with chronic hepatitis B may achieve a good outcome after liver transplantation using lamivudine prophylaxis, and one patient developed recurrent hepatitis B resulting from viral breakthrough at week 53 and survived after retransplantation using adefovir and hepatitis B immune globulin treatment.
Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B–related end‐stage liver disease
TLDR
In patients with hepatitis B–related cirrhosis, pretransplantation recombinant interferon‐α, at the dosage and duration used, has an antiviral effect but does not prevent posttransplantation hepatitis B virus reinfection.
Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
  • Z. Ben‐Ari, E. Mor, Z. Shapira, R. Tur-kaspa
  • Medicine, Biology
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2001
Outcomes in liver transplant recipients with hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade
  • G. Neff, C. O'brien, J. Madariaga
  • Medicine, Biology
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2004
TLDR
Investigation of the association between therapy, HBV breakthrough, and allograft / patient survival in HBV‐positive liver transplant recipients found pre‐LTx HBV viremia should be considered in planning post-LTx prophylaxis.
Liver transplantation in European patients with the hepatitis B surface antigen.
TLDR
In this retrospective study of HBsAg-positive patients, liver transplantation had better results in those who had fulminant hepatitis or delta virus superinfection and reduced mortality.
Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization.
TLDR
An excellent outcome is possible after liver transplantation for chronic HBV disease using HBIg dosed by pharmacokinetic parameters, and quantification of pretransplant serum markers of the HBV antigen load does not predict the intensity of posttransplant treatment required for good clinical outcomes.
...
1
2
3
4
5
...